Home   /  Find a Trial  /  See All Trials HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

see All Trials

Sort by zip code:  





WISDOM Study: Women Informed to Screen Depending on Measures of Risk

Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer (NCT02620852)


To take part in this study, you must be between the ages of 40 and 70 and not have previously been diagnosed with breast cancer or ductal carcinoma in situ (DCIS). You must also be able to receive breast screening at an Athena site: University of California (San Francisco, San Diego, Davis, Los Angeles, and Irvine), or Sanford Health in South Dakota. This study is comparing risk-based screening to annual screening for measuring breast cancer risk and detecting breast cancer. It will help researchers learn if risk-based screening, which helps women learn more about their personal breast cancer risk, is less stressful and as successful at detecting breast cancer. The personalized risk-based screening will take multiple risk factors into consideration, including genetic markers, to determine how often you should have a mammogram.

Digital Tomosynthesis Mammography for Breast Cancer Screening

Tomosynthesis Mammographic Imaging Screening Trial (TMIST) (NCT03233191)


To take part in this study, you must be between ages 45 to 75 and have scheduled or intend to schedule a screening mammogram. You must not have had a screening mammogram within the last 11 months. You must also never have been diagnosed with DCIS or breast cancer. This study is investigating whether digital tomosynthesis (3D) mammography or digital (2D) mammography is better at finding early-stage tumors and improving breast cancer survival. Digital tomosynthesis (3D) mammography is approved by the FDA but is not considered the standard of care for breast cancer screening. Digital (2D) mammography is the standard of care for breast cancer screening.

This is a Phase III trial

Comparison of Whole Breast Screening Ultrasound and Contrast Enhanced Mammography

Comparison of Whole Breast Screening Ultrasound and Contrast Enhanced Mammography for Supplemental Breast Cancer Screening (NCT02310698)


Researchers are trying to identify the best imaging technologies to use along with mammography. Breast ultrasound is sometimes used as an additional test. Studies have shown that it can detect cancers that are not seen on regular mammography. Contrast Enhanced Digital Mammography (CEDM) is an FDA-approved form of mammography. It uses a dye injected into a vein to highlight areas of increased blood supply, which may indicate the presence of cancer cells. CEDM has been shown to detect cancer cells that are not seen on a regular mammogram. This study is comparing the effectiveness of CEDM and breast ultrasound when used along with mammography. To be eligible, a woman must be scheduled to receive contrast enhanced digital mammography alone or with whole breast screening ultrasound or full field digital mammography on the same day or within 30 days of one another.

Empowering Latinas to Obtain Breast Cancer Screenings

Empowering Latinas to Obtain Breast Cancer Screenings (NCT02964234)


To take part in this study, you must be a woman between ages 52 and 75 who identifies as Latina/Hispanic/Chicana, and lives in Pilsen, Little Village, East Side or South Chicago, Illinois. This study is investigating the effects (good and bad) of group sessions designed to empower Latinas to educate others about breast health and breast cancer screening. Researchers think that using a culturally sensitive approach to promote increased participation in breast cancer screening can improve the breast health of Latinas.

A Blood Test for Circulating Tumor Cells for Cancer Screening

Circulating Tumor Cells (CTCs): A Potential Screening Test for Clinically Undetectable Breast Carcinoma (NCT01322750)


Scientists are trying to identify effective new techniques for breast cancer screening. Researchers now believe that breast cancer cells can leave the breast and move through the blood stream to other parts of the body before the tumor is even clinically detectable. Reliable and accurate detection of these circulating tumor cells (CTCs) is now possible with a simple blood test. The goal of this research is see whether a blood test for CTCs could provide a simple, reliable, cost-effective form of breast cancer screening. The aim of this specific study is to evaluate whether individuals with CTCs and no other signs of malignancy have clinically undetectable breast cancer. To be eligible, participants must be military health care beneficiaries.